Teresa Marie Bitetti, President of the Oncology Business Unit at Takeda Pharmaceutical Co Ltd, filed a statement of changes in beneficial ownership on November 4, 2026, disclosing a sale of American Depositary Shares on November 2, 2026.

Key Highlights

  • Shares sold: Bitetti disposed of 46,609 American Depositary Shares (ADS) on November 2, 2026, with transaction code "S."
  • Sale price: The shares were sold at $20.89 per ADS, according to the filing.
  • Remaining ownership: Following the transaction, Bitetti directly held 214,501 ADS beneficially.
  • Dividend equivalent units: The filing notes that 9,100 ADS included in the post-transaction total were received upon vesting of dividend equivalent units not reported in a previously filed statement.
  • Role of reporting person: Bitetti is identified in the filing as an officer with the title President, OBU (Oncology Business Unit) at Takeda Pharmaceutical Co Ltd.
  • Signing authority: The filing was signed by Kate Huleatt, by power of attorney, on behalf of Teresa Bitetti, on November 4, 2026.

Bitetti's ADS Transaction and Beneficial Ownership at Takeda

According to the filing, Teresa Marie Bitetti, who serves as President of the Oncology Business Unit at Takeda Pharmaceutical Co Ltd (NYSE:TAK), reported the disposal of 46,609 American Depositary Shares on November 2, 2026, at a price of $20.89 per share. The transaction code recorded is "S," indicating a sale of securities. The shares disposed of were held directly by the reporting person.

After the reported transaction, Bitetti's direct beneficial ownership stood at 214,501 ADS. The filing includes a footnote disclosing that this total incorporates 9,100 ADS received upon the vesting of dividend equivalent units that had not been included in Bitetti's previously filed ownership statement. No derivative securities transactions were reported in Table II of the filing. Takeda Pharmaceutical is a global biopharmaceutical company, and the Oncology Business Unit that Bitetti leads is one of its key therapeutic area segments.

The filing was submitted individually, as a single-person filing, and was executed under power of attorney by Kate Huleatt on November 4, 2026. No amendment date was listed, indicating this is an original filing rather than a revision of a prior statement.

What Was Disclosed

The filing disclosed that officer Teresa Marie Bitetti sold 46,609 Takeda ADS at $20.89 on November 2, 2026, leaving her with direct beneficial ownership of 214,501 ADS, including 9,100 ADS from previously unreported vested dividend equivalent units.